ViroPharma, Inc.  VPHM
What Does This Company Do?

ViroPharma aims to develop and commercialize drugs to treat rare and infectious diseases. In 2004, the firm acquired its flagship product, Vancocin, for the treatment of Clostridium difficile infection. Through the acquisition of Lev Pharmaceuticals, it also added Cinryze to its product portfolio to fight a rare disorder called hereditary angioedema, or HAE. Additionally, the company markets a seizure treatment in Europe and has a nontoxigenic C. difficile program in testing designed to prevent the recurrence of the disease.

Address 730 Stockton Drive
Exton, PA  19341
Phone 1 610 458-7300
Direct Investment No
Dividend Reinvestment No
Employees 410
Become a Morningstar Premium Member. Enjoy our analyst picks and buy-sell opinions on 3,800 stocks, funds and ETFs. Learn more.

© Copyright 2014 Morningstar, Inc. All rights reserved. Morningstar, the Morningstar logo,, Morningstar Tools are either trademark or service marks of Morningstar, Inc.
Past performance is no guarantee of future results.
Returns will vary and shares may be worth more or less than their original cost when sold.